Search results
Showing 6796 to 6810 of 8314 results
This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).
This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.
This guidance has been updated and replaced by NICE technology appraisal guidance 156.
This guidance has been updated and replaced by NICE technology appraisal guidance 898.
Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)
This guidance has been updated and replaced by NICE technology appraisal guidance TA921.
This guidance has been updated and replaced by NICE guideline CG172.
Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)
This guidance has been updated and replaced by NICE technology appraisal guidance 383.
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)
This guidance has been replaced by NICE technology appraisal guidance 323.
PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)
This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
September 2025: This medtech innovation briefing (MIB) has been withdrawn. This is because the evidence for the technology has changed since the MIB was published. NICE no longer produces or maintains MIBs on behalf of NHS England.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
This guidance has been updated and replaced by NICE interventional procedures guidance 809.
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)
This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.
November 2025: We have withdrawn this quality standard following the launch of new NICE guidelines on suspected sepsis in people aged 16 or over, suspected sepsis in under 16s and suspected sepsis in pregnant or recently pregnant people. This quality standard is now partially replaced by NICE's quality standard on suspected sepsis in over 16s. Quality standards for sepsis in people under 16 and for people who are or have recently been pregnant will publish when paediatric and maternity early warning score tools are reviewed for the next update to the NICE guidelines in 2026. For any queries, please contact qualitystandards@nice.org.uk.